Biologic Therapies Improve Work Outcomes in Spondyloarthritis

By Jack Cush, MD | 14 September 2018

A study from the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBR-AS) shows that biologic use significantly improves work productivity and overall activity impairment.

The BSRBR-AS registry analyzed 577 participants who were employed; 28% were started on biological therapy .

After 12-months of follow-up, those receiving biologic therapy had significantly greater improvements (relative to non-biological therapy) in presenteeism, overall work impairment, and overall activity impairment; however there was no difference in absenteeism.

There is consistent evidence that treatment with biological therapy improves these work and activity measures.

Disclosures:

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may Login/Register to comment.

More Like This

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

By Jack Cush, MD | 02 Nov 2018

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

[...]

Doubling Down on IL-17 In Psoriatic Arthritis

By MedPage Today | 31 Oct 2018

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

[...]

Updates on Psoriatic Arthritis at ACR 2018

By Philip Gardiner | 24 Oct 2018

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.

Axial Spondylitis Abstracts Roundup

By Philip Gardiner | 24 Oct 2018

There have been a number of interesting posters and presentations covering the field of axial spondyloarthropathy. I’ve picked out a few points that I found particularly relevant.

Classification Criteria

NK cells and a Potential Role in the Development of PsA vs PsC (Cutaneous Psoriasis)

By Rachel Tate, DO | 23 Oct 2018

Human NK cells express multiple receptors that interact with HLA class I molecules which, in turn, suppy peptides that bind HLA-E to form CD94/NKG2A NK receptor ligands. These peptides correspond to -22 to -14 residues in the leader sequences of HLA-A, HLA-B and HLA-C binding to the HLA-E site. Methionine – 21 delivers functional peptides in stark contrast to threonine – 21 which does not.

[...]

You are here